Biotech IPOs raise $7.5B as sector’s performance rally flattens
While biopharma financing exit activity has remained strong through the third quarter, public-market performance for the same period was muted, with most of the yearly gains for the U.S. biotech-specific index largely driven by the first half of 2026.
Biotech IPOs raise $7.5B as sector’s performance rally flattens Read More »
